The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity

Hepatology

Volumn 23, Issue 6, 1996, Pages 1429-1435

  Fontana, Robert J ^a   Turgeon, D Kim ^a   Woolf, Thomas F ^b   Knapp, Maegaret J ^b   Foster, Norman L ^a   Watkins, Paul B ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

^c Urology Institute Case Medical Center University Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CAFFEINE; CARBON 13; CHOLINESTERASE INHIBITOR; CYTOCHROME P450; DEXTROMETHORPHAN; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; PHOSPHATIDYLCHOLINE; PLACEBO; TACRINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; ENZYME ACTIVITY; FEMALE; HUMAN; LIVER TOXICITY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029898260     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v23.pm0008675160     Document Type: Article

References (15)

1. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, for the Tacrine Study Group. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-2529.
2. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-1259.
3. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315:1241-1245.
4. Summers WK, Tachiki KH, Kling A. Tacrine in the treatment of Alzheimer's disease. Eur Neurol 1989;29:28-32.
5. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
6. Winker MA. Tacrine for Alzheimer's disease-which patient, what dose? JAMA 1994;271:1023-1024.
7. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-998.
8. Hammel P, Larrey D, Bernuau J, et al. Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease. J Clin Gastroenterol 1990;12:329-331.
9. Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Br Med J 1990;300:495-499.
10. Woolf TF, Pool WF, Kukan M, Bezek S, Kunze K, Trager WF. Characterization of tacrine metabolism and bioactivation using heterologous expression systems and inhibition studies: evidence for CYP1A2 involvement [Abstract]. ISSX Proceedings 1993.
11. Woolf TF, Pool WF, Bjorge S, Chang T, Goel OP, Trager WF. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Drug Metab Dispos Biol Fate Chem 1993;21:1-9.
12. deVries TM, O'Connor-Semmes RL, Koup JR, Forgue ST. Effect of cimetidine and low-dose quinidine on tacrine pharmacokinetics in humans. [Abstract]. Pharm Res 1993;10:8377.
13. deVries TM, Siedlick P, Smithers JA. Effect of multiple-dose tacrine administration on single-dose pharmacokinetics in humans [Abstract]. Pharm Res 1993;10:8333.
14. Madden S, Woolf TF, Pool WF, Park K. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Biochem Pharmacol 1993;46:13-20.
15. Spaldin V, Madden S, Pool WF, Woolf TF, Park BK. The effect of enzyme inhibition on the metabolic activation of tacrine by human liver enzymes. Br J Clin Pharmacol 1994;38:15-22.